new algorithm for second-line dlbcl: the role of car-t therapy
Published 10 months ago • 332 plays • Length 2:10Download video MP4
Download video MP3
Similar videos
-
3:52
updates on the use of car-t therapy for the treatment of dlbcl in the second-line setting
-
2:45
the value of axi-cel as a second-line treatment in r/r lbcl
-
0:58
improving second-line treatments in dlbcl
-
1:34
advances and unmet needs in second-line treatment of dlbcl
-
3:05
car-t therapy in r/r dlbcl
-
![ai collective review 🔴 aicollective review 🔴 [ai collective review]👇](https://i.ytimg.com/vi/dXg5Eg80XsQ/mqdefault.jpg)
17:00
ai collective review 🔴 aicollective review 🔴 [ai collective review]👇
-
4:19
cll: what is 'watch & wait' and what can a patient do during this phase?
-
4:16
car t-cell therapy
-
1:30
insights into nkg2d-targeting car-t cells in r/r aml
-
1:21
approval of axi-cel in second-line for r/r lbcl & label update
-
1:27
advances in btk and bcl2 inhibitors for cll
-
5:00
b-cell lymphoma care: overcoming challenges in the second-line setting
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:26
the impact of covid-19 on car-t therapy
-
1:08
incorporating checkpoint-inhibitors into second-line cll therapy
-
6:51
role of the ebmt registry on reporting car t-cell outcomes
-
1:04
clad-ldac-ven induction therapy in aml: insights from a phase ii trial
-
2:10
engineering donor-derived car-cik cells towards b-all multi-targeting using sleeping beauty platform
-
3:37
tumor-induced double positive t cells display distinct lineage commitment mechanisms and functions
-
3:48
mrd-driven hsct for all
-
1:40
updates on the use of molecular monitoring to detect mrd in aml